BLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
6/8 — Strong
Priority Review
EVKEEZA (evinacumab) by Regeneron is angiopoietin-like 3 inhibitors [moa]. Approved for angiopoietin-like 3 inhibitor [epc]. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVKEEZA (evinacumab) is a monoclonal antibody that inhibits angiopoietin-like 3 (ANGPTL3), a regulator of lipoprotein metabolism. It is indicated for patients with severe hypertriglyceridemia who have inadequate response to other lipid-lowering therapies. The drug works by blocking ANGPTL3 to increase triglyceride clearance and reduce cardiovascular risk.
$7.0MPart D
PeakProduct is at peak lifecycle stage with established market penetration; commercial and medical teams are stable or modestly growing.
Mechanism of Action
Angiopoietin-like 3 Inhibitors
Pharmacologic Class:
Angiopoietin-like 3 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Started Apr 2026
52 enrolled
Homozygous Familial Hypercholesterolemia (HoFH)Coronary Computed Tomography Angiography
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
Started Feb 2023
10 enrolled
Homozygous Familial Hypercholesterolemia
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
Started Jul 2021
21 enrolled
Hypertriglyceridemia
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
Started Jun 2020
20 enrolled
Homozygous Familial Hypercholesterolemia
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Started Jun 2018
52 enrolled
Severe Hypertriglyceridemia (sHTG)
Worked on EVKEEZA at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.